Oncology
Forschungsbereich der Onkologie
Molekulare Mechanismen von Krebserkrankungen zu entdecken und passende Wirkstoffe zu identifizieren stellen wichtige Teilbereiche in der Krebsforschung dar.
Die Tumordiversität ist sehr hoch. Dementsprechend gehört die Krebsforschung zu einem der vielfältigsten Forschungsbereiche und umfasst viele wissenschaftliche Ansätze.
Wir bieten Ihnen deshalb eine konkurrenzlose Produktvielfalt für die onkologische Forschung und Entwicklung im akademischen sowie pharmazeutischen Bereich an.
Klicke auf die Organe und erfahre mehr über verschiedene Krebsarten
Allgemeine Informationen
Onkologen befassen sich mit der Diagnose, Therapie und Nachsorge von Krebs.
Krebs ist eine Klasse von Krankheiten, bei der sich entartete Zellen unkontrolliert teilen und in andere Gewebe eindringen können. Krebszellen können sich über das Blut- und Lymphsystem auf andere Teile des Körpers ausbreiten. Normalerweise wird die Zellproliferation durch viele Mechanismen streng kontrolliert. Darüber hinaus ist das Immunsystem in der Lage, Krebszellen zu erkennen und zu zerstören.
Funktionieren diese Mechanismen nicht richtig oder das Immunsystem kann die Zellen nicht effektiv zerstören, kann es zu einem malignen Tumor kommen. Eine bösartige Neoplasie ist theoretisch überall möglich, es gibt jedoch Krebsarten, die häufiger vorkommen als andere. Bei Männern ist die Prostata und bei Frauen die Brustdrüse die häufigste Tumorlokalisation.
Relevante Produkte für die onkologische Forschung
| Name | Preis | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polyclonal Antibody to Connective Tissue Growth Factor (CTGF) | Anmelden | Polyclonal Antibody to Connective Tissue Growth Factor (CTGF) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Bone Morphogenetic Protein 4 (BMP4) | Anmelden | Polyclonal Antibody to Bone Morphogenetic Protein 4 (BMP4) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Bone Morphogenetic Protein 4 (BMP4) | Anmelden | Polyclonal Antibody to Bone Morphogenetic Protein 4 (BMP4) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Angiopoietin 1 (ANGPT1) | Anmelden | Polyclonal Antibody to Angiopoietin 1 (ANGPT1) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Angiopoietin 1 (ANGPT1) | Anmelden | Polyclonal Antibody to Angiopoietin 1 (ANGPT1) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to E-cadherin | Anmelden | Polyclonal Antibody to E-cadherin | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Vascular Endothelial Growth Factor 183 (VEGF183) | Anmelden | Monoclonal Antibody to Vascular Endothelial Growth Factor 183 (VEGF183) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Vascular Endothelial Growth Factor 145 (VEGF145) | Anmelden | Monoclonal Antibody to Vascular Endothelial Growth Factor 145 (VEGF145) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Connective Tissue Growth Factor (CTGF) | Anmelden | Polyclonal Antibody to Connective Tissue Growth Factor (CTGF) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Erythropoietin Receptor (EPOR) | Anmelden | Polyclonal Antibody to Erythropoietin Receptor (EPOR) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Bone Morphogenetic Protein 4 (BMP4) | Anmelden | Polyclonal Antibody to Bone Morphogenetic Protein 4 (BMP4) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to CUB And Zona Pellucida Like Domains Protein 1 (CUZD1) | Anmelden | Monoclonal Antibody to CUB And Zona Pellucida Like Domains Protein 1 (CUZD1) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) | Anmelden | Monoclonal Antibody to Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 (OCIAD2) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) | Anmelden | Monoclonal Antibody to C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to RAD54 Like Protein 2 (RAD54L2) | Anmelden | Monoclonal Antibody to RAD54 Like Protein 2 (RAD54L2) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) | Anmelden | Monoclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Hyaluronoglucosaminidase 1 (HYAL1) | Anmelden | Monoclonal Antibody to Hyaluronoglucosaminidase 1 (HYAL1) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Golgin A8 Family, Member A (GOLGA8A) | Anmelden | Monoclonal Antibody to Golgin A8 Family, Member A (GOLGA8A) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Insulin Receptor Substrate 3 (IRS3) | Anmelden | Monoclonal Antibody to Insulin Receptor Substrate 3 (IRS3) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Short Palate, Lung And Nasal Epithelium Carcinoma Associated Protein 2 (SPLUNC2) | Anmelden | Monoclonal Antibody to Short Palate, Lung And Nasal Epithelium Carcinoma Associated Protein 2 (SPLUNC2) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Short Palate, Lung And Nasal Epithelium Carcinoma Associated Protein 3 (SPLUNC3) | Anmelden | Monoclonal Antibody to Short Palate, Lung And Nasal Epithelium Carcinoma Associated Protein 3 (SPLUNC3) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Angiopoietin Like Protein 8 (ANGPTL8) | Anmelden | Monoclonal Antibody to Angiopoietin Like Protein 8 (ANGPTL8) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Amphiregulin (AREG) | Anmelden | Polyclonal Antibody to Amphiregulin (AREG) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Angiopoietin 2 (ANGPT2) | Anmelden | Polyclonal Antibody to Angiopoietin 2 (ANGPT2) | ||||||||||||||||
|
||||||||||||||||||
| Polyclonal Antibody to Connective Tissue Growth Factor (CTGF) | Anmelden | Polyclonal Antibody to Connective Tissue Growth Factor (CTGF) | ||||||||||||||||
|
||||||||||||||||||


